Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $23.6252W HIGH $32.24
Volume
2.26 M
Value Traded
69.33 M
Short % Float
0.29%
Days to Cover
2.0
+14.63%Week
+29.59%1 Month
+16.53%3 Month
+18.01%6 Month
-49.18%5 Year
+722.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
30.45 B
EPS (TTM)
1.18
P/E Ratio
26.20
Ent. Value
32.18 B
Total Shares
982.88 M
Float Shares
977.31 M
Insiders
0.01%
Institutions
5.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PHG Catalyst Timeline
Dated clinical, regulatory and corporate events for Koninklijke Philips N.V. NY Registry Shares
Past FDA Catalysts and PDUFA Decisions
How PHG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 97%
Mid Cap(rank 654 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every PHG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in PHG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.6 % | 3.48 M | 61.05 K |
Ownership Trends
PHG Short Interest
Shares sold short, counted twice a month.
0.29%
Short % of Float
of tradable shares sold short
2.8M
Shares Sold Short
+7.1% vs prior count
2.0 Low
Days to Cover
trading days of normal volume to buy every short share back
1.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PHG ranks across every disease it competes in
Competitive Position is a premium feature
See how PHG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPHG News
PHG▲ +8.9%today
Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated
Philips reported a strong Q3 2026 with an 8% rise in comparable order intake and 3% sales growth, totaling EUR 4.4 billion. The adjusted EBITA margin increased to 13.0%, reflecting productivity gains. The company reiterated its 2026 outlook despite ongoing challenges from the Respironics recall and flat sales in certain segments.
Read more →PHGPhilips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab
Philips announced the U.S. launch of the HyperVue Integrated System, designed for efficient coronary imaging and physiology in cath labs. This system integrates DeepOCT+NIRS imaging and X1-FFR physiology assessment, enhancing workflow and accessibility. Philips will showcase this innovation at TCT 2026, alongside its broader imaging portfolio.
Read more →PHGPhilips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform
Philips launched UniGuide 3D Live Guidance, integrating CT planning into live procedures on its Azurion platform. This innovation allows physicians to access CT-derived insights during treatment, enhancing decision-making in PCI and complex vascular procedures. The solution is CE-marked and available in Europe, with plans for broader applications in the future.
Read more →PHGPhilips highlights Integrated Diagnostics’ role in the future of cardiovascular informatics following MediReport acquisition
Philips announced that the acquisition of MediReport will enhance its cardiovascular informatics portfolio. This integration aims to streamline workflows and improve data accessibility, addressing issues highlighted in its Future Health Index 2025 report. Philips will showcase these innovations at the upcoming TCT 2026 conference.
Read more →PHGEXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
Royal Philips announced the EXIT-CVD project, a five-year initiative involving 42 partners across 17 countries. The project aims to transform cardiovascular care through 22 clinical studies involving over 14,000 patients. It focuses on early detection, personalized risk assessment, and advanced therapies to improve patient outcomes in cardiovascular disease.
Read more →PHGPhilips Oral Healthcare Establishes Global Clinical Advisory Board to Help Shape the Future of Oral Care Through Scientific and Clinical Insight
Royal Philips has announced the establishment of the Philips Sonicare Global Clinical Advisory Board. This board consists of 12 international experts who will provide insights to advance Philips Oral Healthcare. Their collective expertise aims to drive meaningful innovation and enhance clinical practices in oral care.
Read more →PHGPhilips Sonicare Next-Generation DiamondClean 9900 Prestige Is Now Available On Amazon; The Brand’s Most Advanced, Intelligent Toothbrush That Gives Users Real-Time Guidance Alongside Signature Brushing Performance
Royal Philips has launched the Philips Sonicare Next-Generation DiamondClean 9900 Prestige, now available on Amazon. This toothbrush features advanced technology, including real-time spatial guidance and an on-device mouth map to improve brushing performance. As the leading power toothbrush brand recommended by dentists in the U.S., Philips continues to innovate in oral care.
Read more →PHGPhilips-led projects win ITEA awards for advancing AI-enabled healthcare innovation
Royal Philips announced that its projects SYMPHONY and AI FORSchung received ITEA Awards of Excellence 2026 for advancing AI in healthcare. SYMPHONY was recognized for connecting healthcare data and workflows, while AI FORSchung was honored for innovations in fiber-optic sensing. Both projects demonstrate significant advancements in clinical applications and data management.
Read more →PHGPhilips OneBlade and Red Bull take self-expression to new heights in Cappadocia, Turkey
Philips OneBlade partnered with Red Bull athlete Marco Waltenspiel to execute a world-first wingsuit hot-air balloon slalom in Cappadocia, Turkey. The event showcased Waltenspiel's unique style and the spirit of self-expression. With speeds reaching 200 km/h, the collaboration emphasizes individuality and the freedom to shape one's look. Philips aims to inspire others to challenge conventions.
Read more →PHGPhilips Launches Revolutionary Lumea® IPL 9900 Pro: the First At-Home Intense Pulsed Light (IPL) Hair Removal Device With Real-Time Audio Guidance That Talks to You During Treatment
Philips has launched the Lumea IPL 9900 Pro, an at-home hair removal device featuring real-time audio guidance. This innovative product aims to enhance user confidence and personalize the hair removal experience. As the leading IPL brand, Philips leverages 25 years of research to ensure effective treatment.
Read more →PHGPhilips advances women’s health ultrasound with new single-transducer solution
Royal Philips has launched the eV14-2v transvaginal transducer, enhancing its ultrasound portfolio for women's health. This device, now FDA cleared and CE marked, offers significant improvements in penetration, resolution, and ergonomics. It aims to streamline workflows in obstetrics and gynecology while improving patient comfort and access to specialty care.
Read more →PHGPhilips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration
Philips and Imricor have announced the launch of a new Interventional MR lab solution, integrating Philips' 1.5T MRI platform with Imricor's iMR systems. This collaboration aims to enhance MR-guided workflows for cardiac procedures. The solution is designed to improve efficiency and effectiveness in interventional MR procedures.
Read more →PHGPhilips selected for ARPA-H program to advance AI-enabled robotic stroke care
Philips has received an award of up to $33.7 million from ARPA-H to enhance AI-enabled robotic stroke care. Collaborating with Johns Hopkins and Boston University, the initiative aims to develop technologies for remote and automated endovascular procedures. This project seeks to improve access to specialized stroke interventions, addressing a critical healthcare challenge.
Read more →PHGPhilips prices EU green bond for EUR 650M
Royal Philips priced EUR 650 million in fixed rate notes due 2034, marking the healthcare industry's first EU Green Bond. The bond, with a coupon of 4.0%, was oversubscribed by 2.7 times. Proceeds will finance activities aligned with Philips' 2030 Impact Ambition, with settlement scheduled for August 28, 2026.
Read more →PHGExor and Philips Extend Long-term Relationship Agreement
Royal Philips and Exor N.V. have updated their long-term relationship agreement, allowing Exor to increase its shareholding in Philips to 22%. This change reflects Exor's confidence in Philips' strategy and governance. Both companies emphasize their commitment to innovation and profitable growth as they execute their strategic plans.
Read more →PHGPhilips expands open patient monitoring ecosystem to help health systems keep sight of patients beyond the bedside
Royal Philips announced new collaborations with various technology partners to enhance its open patient monitoring ecosystem. These partnerships aim to improve continuity of care by integrating wearable technologies for continuous patient monitoring from hospital to home. The initiative supports healthcare systems in maintaining visibility into patient status throughout their recovery journey.
Read more →PHGPhilips Avent introduces new automated SMS-based tool to help moms activate their village during postpartum
Philips Avent has launched the Share the Care Connector, an SMS-based tool aimed at helping new mothers organize support from their community during the postpartum period. The initiative, developed in partnership with March of Dimes, addresses the challenges new moms face in asking for help. The tool allows mothers to invite supporters, customize their needs, and receive actionable support suggestions, thereby reducing the emotional burden of coordination.
Read more →PHGPhilips delivers solid comparable sales growth and margin in Q2; reiterates full year comparable sales growth outlook; Adjusted EBITA and free cash flow outlook increased to reflect US tariff refund
Philips reported Q2 2026 sales of EUR 4.4 billion, reflecting a 4% growth. The adjusted EBITA margin rose to 16.4%, aided by a EUR 186 million US tariff refund. The company reiterated its full-year sales growth outlook of 3%-4.5% and updated its EBITA and free cash flow forecasts. Strong performance was noted across all business segments.
Read more →PHGPhilips receives FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor
Royal Philips received FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor. This sensor enhances pulse oximetry reliability, achieving an Accuracy Root Mean Square (ARMS) value of 1.6%, significantly surpassing the 3% ISO standard. It also shows consistent performance across different skin tones, supporting better clinical decision-making.
Read more →About Koninklijke Philips N.V. NY Registry Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next PHG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime